RLAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Relay Therapeutics Inc (RLAY) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has positive long-term catalysts, hedge fund buying interest, and promising analyst upgrades. While the stock is currently experiencing a short-term dip, its technical indicators, strong pipeline, and financial stability make it a solid long-term investment opportunity.
The MACD histogram is positive at 0.0264, indicating bullish momentum, though it is contracting. RSI is neutral at 51.17, suggesting no overbought or oversold conditions. The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near a key support level (S1: 8.82). Short-term price action may be volatile, but the overall trend appears favorable for long-term growth.
Hedge funds are significantly increasing their holdings, with a 352.49% increase in buying activity last quarter.
Analysts have upgraded the stock with price targets of $13-$14, citing competitive data updates and potential tailwinds from clinical readouts.
Casdin Capital's recent $11.86 million investment in RLAY demonstrates institutional confidence.
The company has a strong cash position of $554.5 million, supporting its pipeline development.
The stock is currently experiencing short-term downward pressure, with a -4.56% pre-market change and -0.62% regular market change.
The company reported a net loss of $54.9 million in Q4 2025, though it showed improvement YoY.
High implied volatility (188.
and a low IV rank (21.
suggest uncertainty in the options market.
In Q4 2025, Relay Therapeutics reported $7.0 million in revenue, flat YoY, and a net loss of $54.9 million, which improved by 27.78% YoY. EPS dropped to -0.32, down 28.89% YoY. The company has a strong gross margin of 100% and ended the year with $554.5 million in cash and equivalents, providing financial stability for its ongoing clinical trials.
Analysts are optimistic about Relay Therapeutics, with recent upgrades from Oppenheimer (Outperform, $14 price target) and Wells Fargo (Overweight, $13 price target). Analysts believe the company's clinical data updates in 2026 could be competitive and drive stock performance.
